Viridian Therapeutics, Inc.

VRDNNASDAQHealthcare● Active

$15.73

$-0.05(-0.32%)

Market Cap$1.4B

P/E Ratio—

52W High$34.29

52W Low$13.18

Avg Volume2.8M

Open$16.05

Beta0.90

Free Cash Flow Financials Revenue

Viridian Therapeutics, Inc. (VRDN) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

VRDN · free cash flow · updated Jun 8, 2026

Core FCF metrics

VRDN · FCF · TTM · margin & CAGR

Free cash flow was −$276.9M for FY2025 (fiscal year ending 2025-12-31), down 18.9% year-over-year The FCF margin was -390.8%.

FY2025 Free Cash Flow−$276.9M▼ -18.9% YoY

Trailing 12M (TTM)−$303.8Mtrailing 4 quarters sum

FCF Margin-390.8%−$276.9M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

VRDN · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$276.4M(0M)−$276.9M▼ 18.9%-390.8%

FY2024−$232.3M(1M)−$232.8M▼ 25.8%—

FY2023−$184.2M(1M)−$185.1M▼ 95.6%—

FY2022−$93.8M(1M)−$94.6M▼ 72.3%—

FY2021−$54.6M(0M)−$54.9M▼ 84.2%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

VRDN · P/FCF · FCF yield · FCF per share

Viridian Therapeutics, Inc. (VRDN) reported negative free cash flow of −$0.28B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

VRDN · cash flow statement · operating / investing / financing

For FY2025, Viridian Therapeutics, Inc. generated −$276.4M in operating cash flow and spent 0M in capital expenditures, yielding −$276.9M in free cash flow.

Operating Activities

−$276.4M

Cash from core business operations

2025-12-31

Investing Activities

−$37.6M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$426.7M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$276.4M) − |CapEx| (0M) = FCF (−$276.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

VRDN vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Viridian Therapeutics, Inc.YOU

VRDN

−$276.9M-18.9%-390.8%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Viridian Therapeutics, Inc. (VRDN) reported free cash flow of −$276.9M for FY2025 (fiscal year ending 2025-12-31), down 18.9% year-over-year. The FCF margin was -390.8%.

Viridian Therapeutics, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 14 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

VRDN free cash flow · 8 questions

Viridian Therapeutics, Inc. free cash flow was −$276.9M for FY2025, down 18.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$303.8M.

VRDN free cash flowVRDN FCFVRDN FCF 2025VRDN free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Viridian Therapeutics, Inc. · Viridian Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026